Farnesyltransferase inhibitors as radiation sensitizers

International Journal of Radiation Biology

Volumn 79, Issue 7, 2003, Pages 569-576

  Brunner, T B ^a   Gupta, A K ^a   Shi, Y ^a   Hahn, S M ^a   Muschel, R J ^a   Mckenna, W G ^a   Bernhard, E J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA HYDROXYFARNESYLPHOSPHONIC ACID; L 778123; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT; RAS PROTEIN; TIPIFARNIB;

CANCER RADIOTHERAPY; CLINICAL TRIAL; CLONOGENIC ASSAY; CONFERENCE PAPER; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; IMMUNOBLOTTING; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; NEUTROPENIA; NONHUMAN; ONCOGENE RAS; OXYGENATION; PHASE 1 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RADIATION; RADIOSENSITIVITY; SIDE EFFECT; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; IMIDAZOLES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

RODENTIA;

EID: 0142178057     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/09553000310001610196     Document Type: Conference Paper

References (46)

1. ADER, I., MULLER, C., BONNET, J., FAVRE, G., COHEN-JONATHAN, E., SALLES, B. and TOULAS, C., 2002, The radioprotective effect of the 24kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogens, 21, 6471-6479.
2. BARRINGTON, R. E., SUBLER, M. A., RANDS, E., OMER, C. A., MILLER, P. J., HUNDLEY, J. E., KOESTER, S. K., TROYER, D. A., BEARSS, D. J., CONNER, M. W., GIBBS, J. B., HAMILTON, K., KOBLAN, K. S., MOSSER, S. D., O'NEILL, T. J., SCHABER, M. D., SENDERAK, E. T., WINDLE, J. J., OLIFF, A. and KOHL, N. E. A., 1998, Farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Molecular and Cellular Biology, 18, 85-92.
3. BERNHARD, E. J., MCKENNA, W. G., HAMILTON, A. D., SEBTI, S. M., QIAN, Y., WU, J. M. and MUSCHEL, R. J., 1998, Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Research, 58, 1754-1761.
4. BERNHARD, E. J., STANBRIDGE, E. J., GUPTA, S., GUPTA, A. K., SOTO, D., BAKANAUSKAS, V. J., CERNIGLIA, G. J., MUSCHEL, R. J. and MCKENNA, W. G., 2000, Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Research, 60, 6597-6600.
5. BUSER, C. A., DINSMORE, C. J., FERNANDES, C., GREENBERG, I., HAMILTON, K., MOSSER, S. D., WALSH, E. S., WILLIAMS, T. M. and KOBLAN, K. S., 2001, High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123. Analytical Biochemistry, 290, 126-137.
6. BUSS, J. E., SOLSKI, P. A., SCHAEFFER, J. P., MACDONALD, M. J. and DER, C. J., 1989, Activation of the cellular proto-oncogene product p21ras by addition of a myristylation signal. Science, 243, 1600-1602.
7. COHEN-JONATHAN, E., EVANS, S. M., KOCH, C. J., MUSCHEL, R. J., MCKENNA, W. G., WU, J. and BERNHARD, E. J., 2001, The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Research, 61, 2289-2293.
8. COHEN-JONATHAN, E., MUSCHEL, R. J., MCKENNA, W. G., EVANS, S. M., CERNIGLIA, G., MICK, R., KUSEWITT, D., SEBTI, S. M., HAMILTON, A. D., OLIFF, A., KOHL, N., GIBBS, J. B. and BERNHARD, E. J., 2000, Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research, 154, 125-132.
9. COX, A. D. and DER, C. J., 1997, Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochimica et Biophysica Acta, 1333, F51-71.
10. ELION, E. A., 1998, Routing MAP kinase cascades. Science, 281, 1625-1626.
11. END, D. W., SMETS, G., TODD, A. V., APPLEGATE, T. L., FUERY, C. J., ANGIBAUD, P., VENET, M., SANZ, G., POIGNET, H., SKRZAT, S., DEVINE, A., WOUTERS, W. and BOWDEN, C., 2001, Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research, 61, 131-137.
12. END, D., SKRZAT, S. and DEVINE, A., 1998, R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems. Proceedings of the American Association of Cancer Research, 39, 270.
13. EVANS, S. M., JOINER, B., JENKINS, W. T., LAUGHLIN, K. M., LORD, E. M. and KOCH, C. J., 1995, Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide]. British Journal of Cancer, 72, 875-882.
14. FENTON, B. M., PAONI, S. F., LEE, J., KOCH, C. J. and LORD, E. M., 1999. Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. British Journal of Cancer, 79, 464-471.
15. FITZGERALD, T. J., DAUGHERTY, C., KASE, K., ROTHSTEIN, L. A., MCKENNA, M. and GREENBERGER, J. S., 1985. Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. American Journal of Clinical Oncology, 8, 517-522.
16. GLOMSET, J. A. and FARNSWORTH, C. C., 1994, Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annual Review of Cell Biology, 10, 181-205.
17. GUPTA, A. K., BERNHARD, E. J., BAKANAUSKAS, V. J., WU, J., MUSCHEL, R. J. and MCKENNA, W. G., 2000, RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiation Research, 154, 64-72.
18. GUPTA, A. K., BAKANAUSKAS, V. J., CERNIGLIA, G. J., CHENG, Y., BERNHARD, E. J., MUSCHEL, R. J. and MCKENNA, W. G., 2001, The Ras radiation resistance pathway. Cancer Research, 61, 4278-4282.
19. GUPTA, A. K., MCKENNA, W. G., WEBER, C. N., FELDMAN, M. D., GOLDSMITH, J. D., MICK, R., MACHTAY, M., ROSENTHAL. D. I., BAKANAUSKAS, V. J., CERNIGLIA, G. J., BERNHARD, E. J., WEBER, R. S. and MUSCHEL, R. J., 2002, Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clinical Cancer Research, 8, 885-892.
20. HAGAN, M., WANG, L., HANLEY, J. R., PARK, J. S. and DENT, P., 2000, Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiation Research, 153, 371-383.
21. HAGEMANN, C. and BLANK, J. L., 2001. The ups and downs of MEK kinase interactions. Cell Signaling, 13, 863-875.
22. HAHN, S. M., BERNHARD, E. J., REGINE, W., MOHIUDDIN, M., HALLER, D. G., STEVENSON, J. P., SMITH, D., PRAMANIK, B., TEPPER, J., DELANEY, T. F., KIEL, K. D., MORRISON, B., DEUTSCH, P., MUSCHEL, R. J. and MCKENNA, W. G., 2002, A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clinical Cancer Research, 8, 1065-1072.
23. HANCOCK, J. F., CADWALLADER, K. and MARSHALL, C. J., 1991, Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO Journal, 10, 641-646.
24. HANCOCK, J. F., MAGEE, A. I., CHILDS, J. E. and MARSHALL, C. J., 1989, All ras proteins are polyisoprenylated but only some are palmitoylated. Cell, 57, 1167-1177.
25. HANCOCK, J. F., PATERSON, H. and MARSHALL, C. J., 1990, A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell, 63, 133-139.
26. HERMENS, A. F. and BENTVELZEN, P. A., 1992, Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Research, 52, 3073-3082.
27. JACKSON, J., COCKRAN, C., BOURNE, J., SOLSKI, P., BUSS, J. and DER, C., 1990, Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proceedings of the National Academy of Sciences, USA, 87, 3042-3046.
28. KASID, U., PFEIFER, A., BRENNAN, T., BECKETT, M., WEICHSELBAUM, R. R., DRITSCHILO, A. and MARK, G. E., 1989, Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science, 243, 1354-1356.
29. KOHL, N., OMER, C., CONNER, M., ANTHONY, N., DAVIDE, J., DESOLMS, S., GIULIANI, E., GOMEZ, R., GRAHAM, S., HAMILTON, K., HANDT, L., HARTMAN, G., KOBLAN, K., KRAL, K., MILLER, P., MOSSER, S., O'NEILL, T., RANDS, E., SCHABER, M., GIBBS, J. and OLIFF, A., 1995, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Medicine, 1, 792-797.
30. LIU, U., CERNIGLIA, G. J., BERNHARD, E. J. and PRENDERGAST, G. C., 2001, RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proceedings of the National Academy of Sciences, USA, 98, 6192-6197.
31. LOBELL, R. B., OMER, C. A., ABRAMS, M. T., BHIMNATHWALA, H. G., BRUCKER, M. J., BUSER, C. A., DAVIDE, J. P., DESOLMS, S. J., DINSMORE, C. J., ELLIS-HUTCHINGS, M. S., KRAL, A. M., LIU, D., LUMMA, W. C., MACHOTKA, S. V., RANDS, E., WILLIANS, T. M., GGRAHAM, S. L., HARTMAN, G. D., OLIFF, A. I., HEIMBROOK, D. C. and KOHL, N. E., 2001, Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Research, 61, 8758-8768.
32. MANGUES, R., CORRAL, T., KOHL, N. E., SYMMANS, W. F., LU, S., MALUMBRES, M., GIBBS, J. B., OLIFF, A. and PELLICER, A., 1998, Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Research, 58, 1253-1259.
33. MCKENNA, W. G., BERNHARD, E. J., MARKIEWICZ, D. A., RUDOLTZ, M. S., MAITY, A. and MUSCHEL, R. J., 1996. Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. Oncogens, 12, 237-245.
34. MCKENNA, W. G., WEISS, M. C., BAKANAUSKAS, V. J., SANDLER, H., KELSTEN, M. L., BIAGLOW, J., TUTTLE, S. W., ENDLICH, B., LING, C. C. and MUSCHEL, R. J., 1990a, The role of the H-ras oncogene in radiation resistance and metastasis. International Journal of Radiation Oncology Biology Physics, 18, 849-859.
35. MCKENNA, W. G., WEISS, M. C., ENDLICH, B., LING, C. C., BAKANAUSKAS, V. J., KELSTEN, M. L. and MUSCHEL, R. J., 1990b, Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Research, 50, 97-102.
36. MENDELSOHN, J. and BASELGA, J., 2000, The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-6565.
37. MYERS, M. P., PASS, I., BATTY, I. H., VAN DER KAAY, J., STOLAROV, J. P., HEMMINGS, B. A., WIGLER, M. H., DOWNES, C. P. and TONKS, N. K., 1998, The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proceedings of the National Academy of Sciences, USA, 95, 13513-13518.
38. NICHOLSON, K. M. and ANDERSON, N. G., 2002, The protein kinase B/Akt signalling pathway in human malignancy. Cell Signaling, 14, 381-395.
39. OMER, C. A., CHEN, Z., DIEHL, R. E., CONNER, M. W., CHEN, H. Y., TRUMBAUER, M. E., GOPAL-TRUTER, S., SEEBURGER, G., BHIMNATHWALA, H., ABRAMS, M. T., DAVIDE, J. P., ELLIS, M. S., GIBBS, J. B., GREENBERG, I., KOBLAN, K. S., KRAL, A. M., LIU, D., LOBELL, R. B., MILLER, P. J., MOSSER, S. D., O'NEILL, T. J., RANDS, E., SCHABER, M. D., SENDERAK, E. T., OLIFF, A. and KOHL, N. E., 2000, Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Research, 60, 2680-2688.
40. PASTORINO, U., ANDREOLA, S., TAGLIABUE, E., PEZZELLA, F., INCARBONE, M., SOZZI, G., BUYSE, M., MENARD, S., PIEROTTI, M. and RILKE, F., 1997, Immunocytochemical markers in stage I lung cancer: relevance to prognosis. Journal of Clinical Oncology, 15, 2858-2865.
41. REUTHER, G. W. and DER, C. J., 2000, The Ras branch of small GTPases: Ras family members don't fall far from the tree. Current Opinions in Cell Biology, 12, 157-165.
42. SEBTI, S. M. and HAMILTON, A. D., 2000, Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Oncogene, 9, 2767-2782.
43. SKLAR., M. D., 1988, The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science, 239, 645-647.
44. VAUPEL, P., THEWS, O. and HOECKEL, M., 2001, Treatment resistance of solid tumors: role of hypoxia and anemia. Medical Oncology, 18, 243-259.
45. WILLUMSEN, B. M., CHRISTENSEN, A., HUBBERT, N. L., PAPAGEORGE, A. G. and LOWY, D. R., 1984a, The p21 ras C-terminus is required for transformation and membrane association. Nature, 310, 383-586.
46. WILLUMSEN, B. M., NORRIS, K., PAPAGEORGE, A. G., HUBBERT, N. L. and LOWY, D. R., 1984b, Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO Journal, 3, 2581-2585.